Suppr超能文献

二氧化硅纳米颗粒的表面功能化:优化载体平台免疫激活特性的策略

Surface Functionalization of Silica Nanoparticles: Strategies to Optimize the Immune-Activating Profile of Carrier Platforms.

作者信息

Punz Benjamin, Johnson Litty, Geppert Mark, Dang Hieu-Hoa, Horejs-Hoeck Jutta, Duschl Albert, Himly Martin

机构信息

Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.

出版信息

Pharmaceutics. 2022 May 21;14(5):1103. doi: 10.3390/pharmaceutics14051103.

Abstract

Silica nanoparticles (SiNPs) are generally regarded as safe and may represent an attractive carrier platform for nanomedical applications when loaded with biopharmaceuticals. Surface functionalization by different chemistries may help to optimize protein loading and may further impact uptake into the targeted tissues or cells, however, it may also alter the immunologic profile of the carrier system. In order to circumvent side effects, novel carrier candidates need to be tested thoroughly, early in their development stage within the pharmaceutical innovation pipeline, for their potential to activate or modify the immune response. Previous studies have identified surface functionalization by different chemistries as providing a plethora of modifications for optimizing efficacy of biopharmaceutical (nano)carrier platforms while maintaining an acceptable safety profile. In this study, we synthesized SiNPs and chemically functionalized them to obtain different surface characteristics to allow their application as a carrier system for allergen-specific immunotherapy. In the present study, crude natural allergen extracts are used in combination with alum instead of well-defined active pharmaceutical ingredients (APIs), such as recombinant allergen, loaded onto (nano)carrier systems with immunologically inert and stable properties in suspension. This study was motivated by the hypothesis that comparing different charge states could allow tailoring of the binding capacity of the particulate carrier system, and hence the optimization of biopharmaceutical uptake while maintaining an acceptable safety profile, which was investigated by determining the maturation of human antigen-presenting cells (APCs). The functionalized nanoparticles were characterized for primary and hydrodynamic size, polydispersity index, zeta potential, endotoxin contamination. As potential candidates for allergen-specific immunotherapy, the differently functionalized SiNPs were non-covalently coupled with a highly purified, endotoxin-free recombinant preparation of the major birch pollen allergen Bet v 1 that functioned for further immunological testing. Binding efficiencies of allergen to SiNPs was controlled to determine uptake of API. For efficacy and safety assessment, we employed human monocyte-derived dendritic cells as model for APCs to detect possible differences in the particles' APC maturation potential. Functionalization of SiNP did not affect the viability of APCs, however, the amount of API physisorbed onto the nanocarrier system, which induced enhanced uptake, mainly by macropinocytosis. We found slight differences in the maturation state of APCs for the differently functionalized SiNP-API conjugates qualifying surface functionalization as an effective instrument for optimizing the immune response towards SiNPs. This study further suggests that surface-functionalized SiNPs could be a suitable, immunologically inert vehicle for the efficient delivery of biopharmaceutical products, as evidenced here for allergen-specific immunotherapy.

摘要

二氧化硅纳米颗粒(SiNPs)通常被认为是安全的,当负载生物药物时,可能代表一种有吸引力的纳米医学应用载体平台。通过不同化学方法进行表面功能化可能有助于优化蛋白质负载,并可能进一步影响其被靶向组织或细胞的摄取,然而,这也可能改变载体系统的免疫特性。为了规避副作用,新型载体候选物需要在药物创新流程的早期开发阶段就针对其激活或改变免疫反应的潜力进行全面测试。先前的研究已经确定,通过不同化学方法进行表面功能化可以提供大量修饰,以优化生物药物(纳米)载体平台的功效,同时保持可接受的安全性。在本研究中,我们合成了SiNPs并对其进行化学功能化,以获得不同的表面特性,使其能够作为变应原特异性免疫疗法的载体系统。在本研究中,粗制天然变应原提取物与明矾联合使用,而不是定义明确的活性药物成分(APIs),如重组变应原,负载到具有免疫惰性和悬浮稳定性的(纳米)载体系统上。本研究的动机是这样一个假设,即比较不同的电荷状态可以调整颗粒载体系统的结合能力,从而在保持可接受的安全性的同时优化生物药物的摄取,这通过测定人抗原呈递细胞(APCs)的成熟情况来进行研究。对功能化纳米颗粒的初级粒径、流体动力学粒径、多分散指数、zeta电位、内毒素污染进行了表征。作为变应原特异性免疫疗法的潜在候选物,不同功能化的SiNPs与主要桦树花粉变应原Bet v 1的高度纯化、无内毒素的重组制剂非共价偶联,用于进一步的免疫学测试。控制变应原与SiNPs的结合效率以确定活性药物成分的摄取情况。为了进行功效和安全性评估,我们使用人单核细胞衍生的树突状细胞作为APCs的模型,以检测颗粒的APCs成熟潜力的可能差异。SiNP的功能化不影响APCs的活力,然而,物理吸附在纳米载体系统上的活性药物成分的量,主要通过巨胞饮作用诱导摄取增加。我们发现不同功能化的SiNP-活性药物成分缀合物在APCs成熟状态上存在细微差异,这证明表面功能化是优化针对SiNPs免疫反应的有效手段。本研究进一步表明,表面功能化的SiNPs可能是一种合适的、免疫惰性的载体,用于高效递送生物药物产品,本研究中变应原特异性免疫疗法就是例证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6802/9146724/938b40e30b69/pharmaceutics-14-01103-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验